Bukwang Pharmaceutical’s headquarters in Sangdo-dong, southwestern SeoulBukwang Pharmaceutical has entered the single representative system of Lee Woo-hyun, chairman of its largest shareholder, OCI Holdings. With the end of the separate representative system, which has continued even after OCI Holdi
BeiGene Korea said on Tuesday it obtained the Ministry of Food and Drug Safety’s approval for Tevimbra Inj. 100mg (ingredient: tislelizumab) to treat esophageal squamous cell carcinoma (ESCC). Specifically, anti-PD-1 immunotherapy Tevimbra has been authorized as monotherapy in adults with unresectab
Sam Chun Dang Pharmaceutical said Tuesday it has signed a contract with an unidentified distributor to supply SCD411 (ingredient aflibercept), a macular degeneration biosimilar referencing Eylea, in five European countries: Germany, Spain, Italy, Switzerland, and Austria.According to the public disc
MSD Korea held a press conference on Monday to celebrate the launch of Vaxneuvance, a 15-valent pneumococcal protein conjugate vaccine, in Korea.The event underscored the need for collaborative efforts and policies to swiftly introduce and implement the new vaccine in Korea's medical sector.Pneumoco
GC's Hunterase, a treatment for Hunter syndrome, has finally obtained full approval, 11 years after receiving conditional approval, the company said on Friday. After being designated as an orphan drug in September 2011, Hunterase, the world's second treatment for Hunter syndrome, received conditiona
AbbVie Korea's interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has expanded its indications to treat moderate-to-severe active Crohn's disease in adult patients (18 and older) following psoriasis and psoriatic arthritis.Skyrizi has won approval and received insurance benefits for treating mo
AbbVie Korea announced Thursday that Aquipta(atogepant), a calcitonin gene-related peptide (CGRP) receptor antagonist, has been approved by the Ministry of Food and Drug Safty (MFDS) for the prevention of migraine in adults. This approval makes AQUIPTA the first once-daily oral CGRP receptor antagon
HanAll Biopharma said Thursday that the monthly sales of its hair loss treatment, Hairgrow (finasteride), have exceeded 1 million tablets.It marked the largest sales volume since its launch in 2007. In 2022, the sales volume of Hairgrow has grown 20 percent on annual average for about five years. In
The supply shortage of Sudafed (ingredient: pseudoephedrine hydrochloride), used for cold and sinus congestion relife, is likely to be resolved in November.An official from the Ministry of Health and Welfare's Pharmaceutical Affairs Division said so at a meeting with journalists covering the ministr
Huons Biopharma, a company specializing in botulinum toxin (BTX), announced Thursday that it has received approval from the Ministry of Food and Safety (MFDS) for the phase 3 Investigational New Drug (IND) clinical trial of its HU-045, a BTX, treating frown lines.HU-045 was developed to address mode
Daewoong Pharma said it has signed a comprehensive memorandum of understanding (MOU) with China Meheco International, a Chinese pharmaceutical import and export company, to export Daewoong's treatment to China.Daewoong expects that through this MOU, the company will be able to accelerate the entry o
Tego Science has successfully demonstrated efficacy in a phase 3 clinical trial of its cell therapy for under-eye wrinkles, fulfilling the conditions for a full license. Tego Sscience's stock price surged to a daily permissible limit on Tuesday.Tego Science released the results of the domestic phase
ST Pharm, an affiliate of Dong-A Socio Group, said it would voluntarily withdraw its investigational new drug (IND) application for STP2250, an mRNA-based Covid-19 prevention booster vaccine, for phase 1/2a clinical trials.The company made this decision due to two main factors: the challenge of recr
Huons Global reported consolidated sales of 190.6 billion won ($142.9 million) and operating income of 31.9 billion won ($24 million) for the third quarter of this year, up 13.8 percent and 75 percent, respectively, from the same period last year. The group's performance was driven by increased inte
GC said it has signed a contract manufacturing organization (CMO) contract for Euvichol, an oral cholera vaccine developed by EuBiologics Co.Under the agreement, GC will be responsible for the contract manufacturing of the finished drug product (DP) of Euvichol until 2026. The two companies also set
Hugel announced Monday that it has recorded 84.8 billion won ($64 million) in sales, 34.6 billion won ($26.1 million) in operating profit and 41.6 billion won ($31.4 million) in net profit for the third quarter of 2023 based on consolidated financial statements.Sales and operating income grew 20 per
Aptabio Therapeutics, a developer of intractable cancer and diabetes complications, announced Monday that it will present preclinical results on the effectiveness of its treatment for Parkinson's disease, APX-NEW, in animal models at the Society of Neuroscience (SFN).The SFN is a large-scale meeting
LG Chem has signed a technology transfer agreement with Peptron to tap into the market for prostate cancer and precocious puberty treatment.Peptron said in a public filing last Friday that it signed a contract with LG Chem for the domestic distribution rights of its prostate cancer and sexual precoc
The global medical community is abuzz with anticipation as the first gene-editing therapy nears potential FDA approval in December.According to industry watchers, the gene-editing therapy Exa-cel, co-developed by CRISPR Therapeutics and Vertex Pharmaceuticals, is nearing potential FDA approval in De
SK biopharmaceuticals said the U.S. patent protection for its epilepsy drug Xcopri (ingredient: cenobamate) has been extended for five years until October 30, 2032.Xcopri acquired a substance patent in Oct. 2007 and received new drug approval in the U.S. in Nov. 2019, with the drug officially being